SABS
SAB Biotherapeutics Inc
3.10$
+4.0%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -4.2% | +110.2% | -48.5% | -5.4% | -18.7% | -0.9% | -0.5% | -1.2% | -0.3% | -1.4% | +110.8% | – | |
| – | -16.0% | +15.0% | -2.6% | +74.4% | -35.7% | -9.1% | +2.3% | -70.1% | +1,587.7% | +72.3% | +132.7% | – | |
| – | – | – | – | +696.0% | -189.9% | – | -11.4% | +72.2% | -550.6% | – | – | – | |
| – | -20.4% | +90.2% | -59.3% | +91.0% | -44.8% | -100.0% | +33.3% | -25.0% | +31,105,066.7% | +5.4% | +161.3% | – | |
| – | +66.1% | +46,108.9% | – | -110.3% | – | -49.9% | +11.3% | -2,598.5% | -98.7% | +3,747.7% | +7.4% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | -171.1% | +1.1% | -79.3% | +1.9% | +1.9% | +3.3% | – | |
| – | – | -100.3% | +11.1% | +167.2% | -93.5% | +294.1% | -0.1% | – | -100.0% | – | +2.6% | – | |
| – | – | -178.6% | – | -351.6% | – | – | – | – | -173.5% | – | -122.3% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.